APR 14, 2020 8:15 AM PDT

Immunotherapy Shows Promise, Destroys Metastatic Brain Tumors

WRITTEN BY: Tara Fernandez

 

Lung cancer is the leading cause of death in both men and women in the U.S., with smokers bearing an elevated risk of the disease. This form of cancer can be asymptomatic in the early stages, escaping detection until it has progressed to an advanced stage, where it can spread, or metastasize, to other regions in the body.

A team of cancer researchers at Yale have published their findings on a promising therapeutic strategy targeting a subset of lung cancer patients with brain metastases. For these patients, which account for about a quarter of all those diagnosed with lung cancer, radiation is often prescribed — a treatment that has significant side effects. The study was published in The Lancet Oncology.

Corresponding author, Sarah Goldberg, Assistant Professor of Medical Oncology at the Yale School of Medicine works as a clinician in the Thoracic Oncology group at the Yale Cancer Center and conducts research on new therapeutic strategies against lung cancer. 

 

 

Here, a cohort of 42 patients were selected for the trial, all of which had brain metastases that had not responded to radiology or had not received treatment. The immunotherapy tested was pembrolizumab (sold under the trade name Keytruda®), a monoclonal antibody administered to patients whose cancers expressed the biomarker PD-L1. Significantly, this checkpoint inhibitor therapy extended patient survival and had drastically fewer side effects than radiation.

Speaking on the significance of the study, Goldberg said, “We have clearly shown, for the first time, that brain metastasis responds to a targeted immunotherapy treatment for lung cancer.” 

“In general, we found that the benefit offered by pembrolizumab to the lungs in patients with advanced lung cancer was mirrored in control of their brain tumors. The brain and body response were the same.”

Interestingly, patients whose brain tumors expressed high levels of PD-L1 experienced longer lasting positive effects from the pembrolizumab therapy, a finding that warrants further investigation.

These results point to a need to reassess the gold standard therapeutic strategies for lung cancer patients with brain metastases. “It might make sense for some patients to try a checkpoint inhibitor first to treat both their lung cancer and brain metastasis. Radiation could follow, if necessary,” said Goldberg.

 



Sources: Yale News, The Lancet Oncology.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
FEB 12, 2020
Drug Discovery & Development
FEB 12, 2020
Does Traditional Chinese Medicine Work Against Coronavirus?
Over 45,000 cases of Wuhan Coronavirus have been reported globally, alongside over 1,100 deaths. Although over 4,700 peo ...
APR 13, 2020
Drug Discovery & Development
APR 13, 2020
Are COVID-19 Antibody Tests a Back-to-Work Pass?
Although treatments and vaccines against COVID-19 may still be months away, antibody tests are becoming more widespread. ...
APR 13, 2020
Immunology
APR 13, 2020
Macrophages: An Origin Story
Macrophages are well-known defense cells of the immune system, responsible for utilizing the cellular breakdown process ...
APR 15, 2020
Immunology
APR 15, 2020
How Malaria Protects Itself from the Immune System
A specific parasitic species causes the most deaths from malaria: Plasmodium falciparum. This parasite does so by avoidi ...
MAY 19, 2020
Immunology
MAY 19, 2020
The Mystery of the Life-Saving Vaccine Solved
In the early 1900s, French bacteriologists Albert Calmette and Camille Guerin spent the better half of a decade developi ...
MAY 17, 2020
Genetics & Genomics
MAY 17, 2020
How Non-Coding Genomic Regions Influence Autoimmune Disease
Scientists have gained new insight into autoimmune and allergic disorders.
Loading Comments...